首页> 外文期刊>Therapeutic Drug Monitoring >The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.
【24h】

The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.

机译:在以麦考酚酸酯为基础的肾移植抗生素治疗期间,麦考酚酸12小时给药前水平的变化幅度和时间过程。

获取原文
获取原文并翻译 | 示例
       

摘要

There is increasing evidence that monitoring predose plasma levels of mycophenolic acid (MPA) is of benefit in renal transplant recipients treated with mycophenolate mofetil (MMF). Concomitant treatment with oral antibiotics leads to a 10% to 30% reduction in MPA area under the curve (AUC)0-12, probably by reducing enterohepatic recirculation (EHR). Because of the timing of EHR (6 to 12 hours postdose), the magnitude of predose MPA level reduction may be disproportionately larger than that of AUC0-12. However, changes in predose MPA levels and the time course over which these changes occur and resolve during antibiotic treatment have not been studied. The purpose of this study was to define the extent and time course of MPA predose level reduction during antibiotic therapy. A total of 64 MMF-treated renal transplant recipients (with tacrolimus cotherapy) were prospectively studied. Clinically indicated cotherapy with either oral ciprofloxacin or amoxicillin with clavulanic acid resulted in a reduction in 12 hour predose MPA level to 46% of baseline within 3 days of antibiotic commencement. No demographic or biochemical variables were associated with the magnitude of MPA level reduction. No further fall in MPA level was seen by day 7, but MPA levels recovered spontaneously to 79% of baseline after 14 days of antibiotics. Levels normalized within 3 days of antibiotic cessation. No changes in daily MMF dose (normalized for body weight) were made during antibiotic treatment. This data should help the clinician to recognize the extent of MPA predose level reduction during antibiotic therapy, and to avoid inappropriate MMF dose escalation and potential risk of toxicity.
机译:越来越多的证据表明,监测麦考酚酸(MPA)的剂量前血浆水平对用麦考酚酸酯(MMF)治疗的肾移植受体有益。口服抗生素的同时治疗可能导致MPA面积在曲线下(AUC)0-12降低10%至30%,这可能是通过减少肠肝再循环(EHR)引起的。由于EHR的时机(给药后6至12小时),给药前MPA降低的幅度可能会比AUC0-12大得多。但是,尚未研究剂量前MPA水平的变化以及在抗生素治疗期间这些变化发生和解决的时间过程。这项研究的目的是确定抗生素治疗期间MPA剂量降低的程度和时间过程。前瞻性研究了总共64位接受MMF治疗的肾移植受者(他克莫司共疗法)。临床表明,口服环丙沙星或阿莫西林与克拉维酸的联合治疗可导致在抗生素开始后3天内,将12小时服药前MPA水平降至基线的46%。没有人口统计学或生化变量与MPA水平降低的幅度相关。到第7天,MPA水平没有进一步下降,但在使用抗生素14天后,MPA水平自发恢复至基线的79%。抗生素停用后3天内的水平恢复正常。在抗生素治疗期间,每日MMF剂量(按体重标准化)没有变化。该数据应有助于临床医生识别抗生素治疗期间MPA剂量降低的程度,并避免不适当的MMF剂量升高和潜在的毒性风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号